文献速递流行病学与生物统计临床试验与 GCP

降压与新发2型糖尿病风险:个体参与者数据荟萃分析

Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.
PubMed 文献 · Lancet · 2021-01-01

该研究利用1973至2008年间22项随机对照试验的个体参与者数据进行荟萃分析,评估降压本身及五类主要降压药对新发2型糖尿病风险的影响。19项试验共145939名参与者的分析显示,收缩压每降低5 mmHg,新发2型糖尿病风险降低11%(HR 0.89,95%CI 0.84-0.95)。与安慰剂相比,ACEI和ARB降低风险,β阻滞剂和噻嗪类利尿剂增加风险,钙通道阻滞剂无实质影响。

要点

  • 收缩压每降低5 mmHg,新发2型糖尿病风险降低11%(HR 0.89,95%CI 0.84-0.95)。
  • 与安慰剂相比,ACEI(RR 0.84)和ARB(RR 0.84)降低新发2型糖尿病风险。
  • 与安慰剂相比,β阻滞剂(RR 1.48)和噻嗪类利尿剂(RR 1.20)增加新发2型糖尿病风险,钙通道阻滞剂无实质影响(RR 1.02)。

核心结论

  • 降压是预防新发2型糖尿病的有效策略。
  • 已确立的降压药物对糖尿病风险的影响在性质和程度上不同,可能源于不同的脱靶效应,其中ACEI和ARB结局最有利。
  • 该证据支持特定类别降压药用于预防糖尿病的适应证,可根据个体糖尿病临床风险进一步细化药物选择。

研究设计与样本

  • 采用一阶段个体参与者数据荟萃分析,合并数据以探讨降压本身对新发2型糖尿病风险的影响。
  • 采用个体参与者数据网络荟萃分析探讨五类主要降压药对新发2型糖尿病风险的差异效应。
  • 数据来自降压治疗试验者协作组(英国牛津大学)获取的1973至2008年间22项研究。
  • 纳入所有一级和二级预防试验,比较特定类别降压药与安慰剂或其他类别降压药,每个随机分配组随访至少1000人年。
  • 排除基线已知诊断糖尿病者及在现患糖尿病患者中进行的试验。

主要发现

  • 一阶段个体参与者数据荟萃分析纳入19项随机对照试验的145939名参与者(88500名[60.6%]男性,57429名[39.4%]女性)。
  • 个体参与者数据网络荟萃分析纳入22项试验。
  • 中位随访4.5年(IQR 2.0)后,9883名参与者被诊断为新发2型糖尿病。
  • 所有试验中收缩压降低5 mmHg使2型糖尿病风险降低11%(HR 0.89,95%CI 0.84-0.95)。
  • 与安慰剂相比,ACEI(RR 0.84,95%CI 0.76-0.93)和ARB(RR 0.84,95%CI 0.76-0.92)降低新发2型糖尿病风险;β阻滞剂(RR 1.48,95%CI 1.27-1.72)和噻嗪类利尿剂(RR 1.20,95%CI 1.07-1.35)增加风险,钙通道阻滞剂无实质影响(RR 1.02,95%CI 0.92-1.13)。

临床怎么用

  • 作者认为,该证据支持特定类别降压药用于预防糖尿病的适应证,可根据个体糖尿病临床风险进一步细化药物选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Blood pressure lowering is an established strategy for preventing microvascular and macrovascular complications of diabetes, but its role in the prevention of diabetes itself is unclear. We aimed to examine this question using individual participant data from major randomised controlled trials. METHODS: We performed a one-stage individual participant data meta-analysis, in which data were pooled to investigate the effect of blood pressure lowering per se on the risk of new-onset type 2 diabetes. An individual participant data network meta-analysis was used to investigate the differential effects of five major classes of antihypertensive drugs on the risk of new-onset type 2 diabetes. Overall, data from 22 studies conducted between 1973 and 2008, were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We included all primary and secondary prevention trials that used a specific class or classes of antihypertensive drugs versus placebo or other classes of blood pressure lowering medications that had at least 1000 persons-years of follow-up in each randomly allocated arm. Participants with a known diagnosis of diabetes at baseline and trials conducted in patients with prevalent diabetes were excluded. For the one-stage individual participant data meta-analysis we used stratified Cox proportional hazards model and for the individual participant data network meta-analysis we used logistic regression models to calculate the relative risk (RR) for drug class comparisons. FINDINGS: 145 939 participants (88 500 [60·6%] men and 57 429 [39·4%] women) from 19 randomised controlled trials were included in the one-stage individual participant data meta-analysis. 22 trials were included in the individual participant data network meta-analysis. After a median follow-up of 4·5 years (IQR 2·0), 9883 participants were diagnosed with new-onset type 2 diabetes. Systolic blood pressure reduction by 5 mm Hg reduced the risk of type 2 diabetes across all trials by 11% (hazard ratio 0·89 [95% CI 0·84-0·95]). Investigation of the effects of five major classes of antihypertensive drugs showed that in comparison to placebo, angiotensin-converting enzyme inhibitors (RR 0·84 [95% 0·76-0·93]) and angiotensin II receptor blockers (RR 0·84 [0·76-0·92]) reduced the risk of new-onset type 2 diabetes; however, the use of β blockers (RR 1·48 [1·27-1·72]) and thiazide diuretics (RR 1·20 [1·07-1·35]) increased this risk, and no material effect was found for calcium channel blockers (RR 1·02 [0·92-1·13]). INTERPRETATION: Blood pressure lowering is an effective strategy for the prevention of new-onset type 2 diabetes. Established pharmacological interventions, however, have qualitatively and quantitively different effects on diabetes, likely due to their differing off-target effects, with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers having the most favourable outcomes. This evidence supports the indication for selected classes of antihypertensive drugs for the prevention of diabetes, which could further refine the selection of drug choice according to an individual's clinical risk of diabetes. FUNDING: British Heart Foundation, National Institute for Health Research, and Oxford Martin School.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021. PMID: 34774144. doi:10.1016/S0140-6736(21)01920-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。